Review paper<br>The latest recommendations for the management of ankylosing spondylitis

Ewa Stanisławska-Biernat

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2006
vol. 44

Send email

Copy url:

abstract:

Review paper
The latest recommendations for the management of ankylosing spondylitis

Ewa Stanisławska-Biernat

Reumatologia 2006; 44, 6: 330–334

Online publish date: 2006/12/15

View full text Get citation

Ankylosing spondylitis (AS) is a chronic inflammatory disease that leads to loss of function and disability in patients. AS is responsible for significant direct and indirect socioeconomic costs. Few studies have been performed on the treatment of patients with AS with disease-modifying antirheumatic drugs, none of which have proved clearly effective in axial disease. In the last few years the results of randomised controlled trials have raised good evidence that TNF-α blockade is very effective in AS and other spondyloarthropathies. Recently published guidelines for treatment of AS are discussed. There is a need for safety and socioeconomic data for long-term treatment with biologicals.

keywords:

ankylosing spondylitis, treatment, biologic treatment, anti-TNF

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

Review paperThe latest recommendations for the management of ankylosing spondylitis

Ewa Stanisławska-Biernat

ankylosing spondylitis, treatment, biologic treatment, anti-TNF

Review paper
The latest recommendations for the management of ankylosing spondylitis